H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy

H.C. Wainwright has reaffirmed a Buy rating and set a $8.00 price target on Prelude Therapeutics (NASDAQ:PRLD). The company's stock is currently trading at $3.56, indicating substantial upside potential based on the analyst's target. Wall Street analysts remain optimistic, with a Strong Buy consensus on Prelude. The biotech firm recently announced a clinical trial collaboration and supply agreement with Eli Lilly, focusing on the KAT6A-selective degrader, PRT13722.

Prelude anticipates beginning patient enrollment in a Phase 1 trial for PRT13722 in the fourth quarter of 2026, both as a standalone treatment and in combination with abemaciclib and imlunestrant. Preclinical data from the AACR 2026 conference revealed that PRT13722 offers a more comprehensive shutdown of KAT6A regulatory pathways compared to dual KAT6A/B inhibitors like prifetrastat.

In vivo tests showed superior anti-tumor efficacy for PRT13722, both as monotherapy and in combination with fulvestrant or abemaciclib, when compared to prifetrastat alone or in combination. Prelude Therapeutics maintains a robust balance sheet, with a current ratio exceeding 4.0. The company's research portfolio includes at least 12 other KAT6-targeted therapies currently in development.

Despite recent losses, Prelude's stock has delivered an impressive 174% return over the past year, as per InvestingPro data. H.C. Wainwright's valuation analysis does not yet factor in any revenue contribution from PRT13722. For investors seeking further insights, the comprehensive Pro Research Report is available on InvestingPro, along with seven additional ProTips.

Prelude Therapeutics has also announced collaborations with Eli Lilly, evaluating PRT13722 in combination with Verzenio and Inluriyo for HR+/HER2- breast cancer patients. JPMorgan initiated coverage on the company with an Overweight rating and a $12.00 price target, noting the potential of PRT12396, a JAK2V617F mutant selective inhibitor in phase 1 trials for V617F+ myeloproliferative neoplasms.

H.C. Wainwright's decision to reiterate a Buy rating, despite Incyte's discontinuation of its JAK2V617F inhibitor program, underscores the company's growing significance in the field. CSPC Pharmaceutical's initiation of a Phase 1 trial in China for a KAT6A/B inhibitor further highlights ongoing research in this area.